News
Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
On 13 January 2025, GlyTherix Ltd and Eckert & Ziegler announced the expansion of their existing Lutetium-177-based collaboration with a global supply agreement for Actinium-225. Eckert & Ziegler will provide high-quality Ac-225 to support GlyTherix’s clinical...
GlyTherix to Showcase its targeted radiotherapy technology at JPM Healthcare Week 2025 + Corporate Updates
Exciting News from GlyTherix at JPM Healthcare Week 2025!We’re thrilled to announce that GlyTherix, a leader in targeted radiotherapy, will be showcasing its cutting-edge technology at two major events during JPM Healthcare Week in San Francisco. Wuxi Apptec Global...
GlyTherix and Nusano Announce Alpha and Beta Isotope Supply Agreement
GlyTherix and Nusano, a physics company transforming the production of radioisotopes, today announced a supply agreement for non-carrier-added lutetium-177 (Lu-177). The agreement also provides GlyTherix access to Nusano’s future actinium-225 (Ac-225) production,...
GlyTherix at EANM’24
We are pleased to announce GlyTherix is presenting an e-poster titled "Determination of Optimal Imaging Dose of [89Zr]Zr-DFO-Miltuximab and Maximum Tolerated Therapeutic Dose of [177Lu]Lu-DOTA-Miltuximab." This will showcase our groundbreaking research in the field of...
GlyTherix and Eckert & Ziegler Sign Agreement for Lutetium-177 Supply
Exciting News in Targeted Radiotherapy! GlyTherix Ltd has signed a global clinical supply agreement with Eckert & Ziegler, a leader in isotopes for nuclear medicine. This collaboration will provide GMP-grade Lutetium-177 chloride for GlyTherix's clinical trials,...
GlyTherix to Partner with SHINE Technologies for Advancing Targeted Radiotherapy in Aggressive Cancers
GlyTherix is pleased to announce a new global clinical supply agreement with Wisconsin-based SHINE Technologies, a pioneer in next-generation fusion-based technology and North America's largest producer of non-carrier added lutetium-177 (n.c.a. Lu-177) chloride. SHINE...
GlyTherix Establishes its Initial US Development and Manufacturing Capabilities with 3D Imaging LLC
GlyTherix Ltd is pleased to announce the execution of a Master Service Agreement with 3D Imaging LLC (3DI), a Contract Development and Manufacturing Organization (CDMO), for the manufacture of GlyTherix’s targeted radiotherapy antibody products for its US clinical...
GlyTherix presentation at AusBiotech 2024
GlyTherix is thrilled to be invited to speak at the AusBiotech 2024 National Conference. In a session titled “The rise of radiopharmaceuticals: How Australian biotech is at the forefront of this resurgence” GlyTherix CEO, Dr Brad Walsh will be presenting with other...
GlyTherix signed the HOA with Cyclowest
We are pleased to work with the Cyclowest team, Nat Lenzo and Thomas Tuchyna to bring new targeted radiotherapies to patients. Cyclowest started to produce Zirconium-89 with a plan to obtain TGA licensing for several Zr-89 products over the next 12 months. GlyTherix...
2024 BioShares Biotech Summit
We are pleased to be attending the upcoming summit in Fremantle this coming Friday and Saturday. Looking forward to discussing GlyTherix Ltd's targeted radiotherapy program which holds tremendous potential to enhance treatment efficacy while minimizing adverse...
GlyTherix Roadshow
Meet with targeted radiotherapy company GlyTherix Ltd in Boston and New York. Next week Brad Walsh, CEO and David Burdis, CFO will be joining with their advisors Atoll Financial Group for a roadshow in Boston Monday May 6 and Tuesday May 7 followed by New York May 8...
GlyTherix Appoints Dr Colin Hayward as Clinical Advisory Board Member
Sydney (Australia) – April 3, 2024. GlyTherix Ltd (GlyTherix) an Australian immuno-oncology company specialising in developing targeted radiotherapies for solid tumors today announces that Dr Colin Hayward has joined GlyTherix’s Clinical Advisory Board. Based in North...
Dr Brad Walsh will be presenting the GlyTherix story at Radiopharma Day
GlyTherix is pleased to announce Dr Brad Walsh will be presenting the GlyTherix Ltd story at 1.15pm on Friday March 1 at the B. Riley Securities Radiopharma Day. Email radiopharma@brileyfin.com for more details.
GlyTherix US Expansion
GlyTherix Ltd is pleased to announce Alan Harris MD PhD has taken an expanded role as a Strategic and Scientific Advisor to assist the company increase its current US footprint including retention of key US-based personnel. He will work closely with GlyTherix’s Dr...
GlyTherix appoints Atoll Financial Group as financial advisor for its Series B raise of up to USD50M
GlyTherix Ltd is pleased to advise it has appointed Atoll Financial Group as its financial advisor for its Series B raise of up to USD50M. This round will enable the company to push forward its targeted radiotherapy program Phase 1b trial and includes funding for its...
Elcin Zan M.D. joins the GlyTherix Advisory Board
GlyTherix Ltd is so pleased to announce another esteemed clinician has joined our advisory board. Elcin Zan, MD is a dual board-certified radiologist specializing in Nuclear Medicine and Neuroradiology. She is an Assistant Professor of Clinical Radiology at Weill...
Meet Us at JP Morgan Week in San Francisco on 8 – 11 January
Meet us at J.P. Morgan between January 8 and 11 in San Francisco, CA. We are so pleased to have an awesome team from GlyTherix with us in San Francisco. It is the perfect time to get involved with us as the targeted radiotherapy field keeps going from strength to...
Dr Alan Harris joins our Advisory Board
We are excited to welcome Dr Alan Harris to our Advisory Board. Dr Harris comes with a long history of success in the radiopharmaceutical space as a researcher, commercializer and businessman (see here). The company has been guided by Alan during the first phase of...
GlyTherix Ltd and the South Australian Health and Medical Research Institute Limited (SAHMRI) Has Entered into Collaborative Research Agreement
Sydney, Australia – 10 Oct 2023. GlyTherix Ltd (GlyTherix), an Australian immuno-oncology company specialising in developing antibody radiopharmaceuticals for solid tumours is pleased to announce that it has entered into a Collaborative Research Agreement with the...
GlyTherix Ltd Announces Cyclowest Holdings as Cornerstone Investor and exclusive Manufacturing, Supply & Distribution partner for 89Zirconium
Sydney, Australia – July 22, 2023. GlyTherix Ltd (GlyTherix), an Australian immuno-oncology company specialising in developing antibody radiopharmaceuticals for solid tumours is pleased to announce a cornerstone investment by Cyclowest Holdings Pty Ltd (Cyclowest) in...
Key GlyTherix patent finalises in-country registration journey
GlyTherix is pleased to announce that our key composition of matter patent titled “Monoclonal Anti-GPC-1 antibodies and uses thereof” has now completed in-country registration. We now have protection in 21 countries including US, UK, Europe, China, Japan, and...
GPC-1 – a first-in-class “theranostic” oncology asset – The Evidence
Learn more about our Glypican-1 (GPC-1) antibody as a targeted therapy for delivering a radioactive payload to cancer cells. The evidence for GPC-1 being a key target in cancer therapy continues to expand rapidly. This includes recent publications with our...
GlyTherix Ltd signs Lutetium-177 supply agreement with ANSTO
ANSTO to supply Lutetium-177 for GlyTherix’s Phase Ib therapeutic trial in patients with prostate, pancreatic and bladder cancers Phase Ib basket clinical trial expected to start in late 2023 Sydney, Australia – February 21, 2023 – GlyTherix Ltd, an Australian...
GlyTherix and The University of Queensland join forces in ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals
GlyTherix Ltd today announces that it has been jointly awarded a $4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part of a consortium of applicants led by The University of Queensland....
GlyTherix IP News
We are pleased to announce that our key composition of matter patent for GlyTherix Ltd’s proprietary antibody to GPC-1 is now registered in 20 countries including US, Australia, China and Japan as well as several key European countries. The company’s IP estate is...
High-Yield GMP-Compliant Primary Cell Bank Established for Miltuximab®
Date, July 21 2022: Sydney. GlyTherix is pleased to announce the successful completion of its high-yield GMP-grade stable cell line development program for its proprietary antibody Miltuximab® in partnership with international biologics manufacturer GenScript ProBio...
GlyTherix is a partner in ARC Hub for Advanced Manufacture of Targeted Radiopharmaceuticals
Congratulations to Prof Kris Thurecht for the funding of the ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR). GlyTherix Ltd is a proud partner organisation and is excited to see Australian radioimmunotherapy technology getting this...
GlyTherix awarded NSW Government TechVoucher to evaluate efficacy of our cancer antibody Miltuximab®
GlyTherix is pleased to announce the award of a $50,000 COVID-19 TechVoucher by the NSW Government through Investment NSW that will provide funding support to collaborate with ANSTO’s world-leading radiochemistry and preclinical imaging teams. Funds will be used to...
GlyTherix is a recipient of the first round of the TIA pipeline accelerator 2020-21 scheme
GlyTherix Ltd is proud to be a recipient of the first round of the Pipeline Accelerator 2020-21 scheme from Therapeutic Innovation Australia (TIA). Round 1 saw the award of $685,000 to 21 projects. Our project “Optimisation and characterisation of Miltuximab®-DFO...
Carina Biotech and GlyTherix enter into CAR-T partnership
PRESS RELEASE September 10, 2020 Adelaide, Australia and Sydney, Australia. CAR-T biotherapeutics company Carina Biotech and immuno-oncology company GlyTherix are pleased to announce a co-development agreement that could result in a promising new CAR-T therapy that is...
GlyTherix Awarded $3 Million Co-operative Research Centre Project Grant
16th July 2020: Sydney • Project boasts a dream team of world class partners across antibody manufacturing and clinical trials • Grant will support development of national capability in manufacture and distribution of radioimmuno-oncology drugs • GlyTherix’s...
Industry News: MTPConnect’s COVID-19 Impact Report
Explore the impact of the pandemic lockdown on medtech, biotech and pharma sectors in Australia by downloading MTPConnect’s COVID-19 Impact Report.
Four New Peer Reviewed Papers Underline the Strength of the GlyTherix Technology
Tuesday 19th May 2020: Sydney GlyTherix Ltd (GlyTherix) is pleased to report publication of four new peer reviewed papers covering both basic science as well as pre-clinical studies around our proprietary novel target, Glypican-1 and our lead antibody to this target,...